ReviewDiabetes, obesity & metabolism2022

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.

Ralph A DeFronzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.